NRX Pharmaceuticals, Inc. (NRXP) Stock Analysis and Metrics

NRX Pharmaceuticals

NASDAQ: NRXP

$3.76 ▼ -0.36 (-8.63%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap137.57 Mn

P/E-7.58

P/S61.80

Div. Yield0.00

Add ratio to table…

About

NRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company that develops novel therapeutics for central nervous system disorders including suicidal depression chronic pain post traumatic stress disorder and schizophrenia. The company conducts its research and development through the wholly owned subsidiary NeuroRx Inc. which focuses on molecules that modulate the NMDA receptor to enhance neuroplasticity. NRx Pharmaceuticals, Inc. is also the founder and majority owner of HOPE Therapeutics Inc. a medical services organization that provides interventional psychiatry care combining ketamine infusion transcranial magnetic stimulation Spravato administration hyperbaric therapy digital therapeutics and medication management. Its lead drug candidates consist of NRX 100 a preservative free intravenous ketamine formulation KETAFREE a generic ketamine product intended for the existing anesthetic market and NRX 101 an oral fixed dose combination of D cycloserine and lurasidone aimed at reducing suicidality and affective symptoms. All programs are advancing through preclinical work manufacturing scale up and regulatory interactions with the U. S. Food and Drug Administration.

Revenue at NRx Pharmaceuticals, Inc. currently derives mainly from the clinical operations of HOPE Therapeutics which began generating income in the fourth quarter of 2025 after acquiring its first clinic Dura Medical in Florida. HOPE now operates five clinical sites in the state and offers services such as intravenous ketamine treatment transcranial magnetic stimulation sessions Spravato nasal spray dosing and psychotherapy to patients with treatment resistant depression and post traumatic stress disorder. The company expects HOPE revenue to rise as it opens additional clinics in Boston Denver and other markets and as it expands its provider network through partnerships and minority investments. Looking forward NRx Pharmaceuticals, Inc. anticipates future product revenue from the commercialization of its drug candidates pending regulatory approval including KETAFREE for the generic ketamine market estimated at over seven hundred fifty million dollars annually NRX 100 for the suicidal depression indication that could address a multi billion dollar opportunity and NRX 101 for bipolar depression and related uses. The firm also supplements its cash flow with non dilutive funding such as government grants partnership agreements and occasional equity offerings to support clinical trials and manufacturing activities.

NRx Pharmaceuticals, Inc. competes in a sector that includes large pharmaceutical companies specialty biotech firms and established providers of neuropsychiatric therapeutics. In the ketamine space the firm faces competition from generic manufacturers of ketamine hydrochloride and from Janssen Pharmaceuticals which markets Spravato esketamine nasal spray for treatment resistant depression and reported roughly two billion dollars in sales in 2025. The generic ketamine market itself exceeds seven hundred fifty million dollars per year providing a sizable opportunity for KETAFREE if approved. For NRX 101 competitors include other antidepressants such as selective serotonin reuptake inhibitors serotonin norepinephrine reuptake inhibitors and atypical antipsychotics like lurasidone quetiapine and aripiprazole that are commonly prescribed for bipolar disorder and suicidal ideation. The company s competitive advantages arise from its proprietary formulations such as the preservative free ketamine intended to reduce injection related adverse effects and its patent portfolio covering compositions of matter methods of use and manufacturing processes. Regulatory milestones including Fast Track designation for NRX 100 and Breakthrough Therapy designation for NRX 101 may allow accelerated review pathways and broader clinical development flexibility. Moreover NRx Pharmaceuticals, Inc. leverages real world evidence collaborations with organizations like Osmind to enrich its safety and efficacy data sets and it pursues partnerships with device manufacturers to combine its drugs with neuromodulation technologies such as transcranial magnetic stimulation.

NRx Pharmaceuticals, Inc. serves patients who experience severe depression suicidal thoughts post traumatic stress disorder and related neuropsychiatric conditions that often respond poorly to standard oral antidepressants. Its HOPE Therapeutics clinics deliver direct care to these individuals offering services such as ketamine infusions transcranial magnetic stimulation sessions Spravato administration and psychotherapy under the supervision of licensed physicians. The company also aims to market its drug candidates to psychiatrists neurologists primary care physicians and other prescribers who treat adults with major depressive disorder bipolar disorder and PTSD in outpatient clinics inpatient units and specialty mental health centers. While the filing does not list specific customer names the target population includes hospitals health systems community mental health centers and private practice providers across the United States that seek innovative therapies for resistant mood disorders. According to public health data millions of Americans experience suicidal ideation each year representing a substantial addressable audience for the company s neuroplasticity focused approach.

Investment Thesis

▲ Bull case

NRXP is positioned to capitalize on a critical gap in the U.S. ketamine supply chain with its KETAFREE product, which addresses a structural shortage exacerbated by the growing ketamine clinic market and the limitations of traditional manufacturing. The company has achieved VAI status for its manufacturing site and initiated commercial-scale production using blow-fill seal (BFS) technology, enabling a throughput of 1 million units per week at substantially lower cost than glass vial-based methods. This capability directly mitigates the ASHP-listed shortage of sterile intravenous ketamine, which has persisted due to supply chain fragility and discontinuous availability. Unlike competitors reliant on compounding pharmacies—often the only source for clinics unable to access wholesalers—NRXP offers FDA-approved, preservative-free ketamine with U.S.-based production, creating a reliable alternative amid rising demand from both psychiatric and pain management indications. The appointment of Glenn Tyson as Chief Commercial Officer, with a proven track record in launching SUBLOCADE at Indivior, signals strong execution readiness for commercialization, particularly in navigating payer outreach and major account acquisition. With the company debt-free, $7 million raised post-quarter, and sufficient cash for immediate operating needs, NRXP has de-risked its near-term financial profile while building scalable infrastructure. The convergence of regulatory progress, manufacturing scalability, and unmet clinical demand positions KETAFREE to capture share in a market where the generic ketamine segment exceeds $750 million annually, excluding the significant shadow market served by compounding pharmacies, all of which remains underappreciated by investors focused solely on near-term losses.
NRXP’s NRX-100 program benefits from a powerful confluence of regulatory tailwinds that could accelerate approval and expand market potential beyond current expectations. The FDA’s willingness to accept real-world evidence (RWE) from over 65,000 patients via the Osmind partnership—as confirmed in the Type C meeting—reduces the need for costly and time-intensive additional trials, with the NDA expected in Q2 FY26. This is further amplified by President Trump’s executive order on Accelerating Medical Treatment for Serious Mental Illness, which explicitly directs FDA to prioritize psychedelic medicines for depression, PTSD, and suicidality and to award National Priority Vouchers to qualifying drugs—NRXP has already applied for this voucher. Congressional appropriations language reinforcing the use of RWE in approvals for suicidal depression and PTSD creates a bipartisan, structural shift in regulatory strategy that NRXP is uniquely positioned to exploit. With Fast Track designation already secured, the company is entitled to priority review, and the potential voucher could yield significant financial upside through resale or tax savings. The broader indication sought—depression in patients who may have suicidality, affecting over 10 million Americans—dwarfs the narrow suicidality-only label of SPRAVATO, which generates ~$2 billion annually despite lacking suicidality reduction in its labeling. NRXP’s data foundation, combining over 1,000 patients from clinical trials with 65,000+ real-world records, provides a robust, real-world-validated dataset that aligns with FDA’s evolving stance, potentially enabling faster approval and broader adoption than anticipated.
The MIND1 trial for NRX-101 represents a high-potential, non-dilutive catalyst that could transform the depression treatment landscape by combining D-cycloserine with robotic-assisted TMS via an accelerated ONE-D protocol. FDA clearance to proceed, anticipated federal funding from military treatment facilities, and collaboration with HOPE Therapeutics clinics and academic institutions create a uniquely supported trial design targeting 400 participants. Preclinical and early clinical data suggest that adding D-cycloserine to TMS doubles clinical response and increases remission eightfold for suicidality—effects that, if replicated, would position NRX-101 as a breakthrough adjunct therapy in a market exceeding $1 billion. The involvement of NRx Defense Systems, led by a former DARPA program manager, and the partnership with Zeta Surgical—whose AI-powered neuro navigation platform has FDA 510(k) clearance—adds technological differentiation and credibility. Crucially, the trial’s focus on frontline troops and first responders addresses a critical unmet need: depression and PTSD carry a fivefold increased risk in these populations, and standard antidepressants often disqualify them from deployment, making a rapid, effective non-pharmacological alternative both a healthcare imperative and a force readiness priority. If positive, the MIND1 trial could support approval based on a single study due to the heightened regulatory priority around suicidality, reducing future development costs and accelerating time-to-market. This pipeline asset remains under-discussed in investor conversations focused on KETAFREE and NRX-100, yet it offers a distinct, high-impact pathway to long-term value creation.

NRXP is positioned to capitalize on a critical gap in the U.S. ketamine supply chain with its KETAFREE product, which addresses a structural shortage exacerbated by the growing ketamine clinic market and the limitations of traditional manufacturing. The company has achieved VAI status for its manufacturing site and initiated commercial-scale production using blow-fill seal (BFS) technology, enabling a throughput of 1 million units per week at substantially lower cost than glass vial-based methods. This capability directly mitigates the ASHP-listed shortage of sterile intravenous ketamine, which has persisted due to supply chain fragility and discontinuous availability. Unlike competitors reliant on compounding pharmacies—often the only source for clinics unable to access wholesalers—NRXP offers FDA-approved, preservative-free ketamine with U.S.-based production, creating a reliable alternative amid rising demand from both psychiatric and pain management indications. The appointment of Glenn Tyson as Chief Commercial Officer, with a proven track record in launching SUBLOCADE at Indivior, signals strong execution readiness for commercialization, particularly in navigating payer outreach and major account acquisition. With the company debt-free, $7 million raised post-quarter, and sufficient cash for immediate operating needs, NRXP has de-risked its near-term financial profile while building scalable infrastructure. The convergence of regulatory progress, manufacturing scalability, and unmet clinical demand positions KETAFREE to capture share in a market where the generic ketamine segment exceeds $750 million annually, excluding the significant shadow market served by compounding pharmacies, all of which remains underappreciated by investors focused solely on near-term losses.
NRXP’s NRX-100 program benefits from a powerful confluence of regulatory tailwinds that could accelerate approval and expand market potential beyond current expectations. The FDA’s willingness to accept real-world evidence (RWE) from over 65,000 patients via the Osmind partnership—as confirmed in the Type C meeting—reduces the need for costly and time-intensive additional trials, with the NDA expected in Q2 FY26. This is further amplified by President Trump’s executive order on Accelerating Medical Treatment for Serious Mental Illness, which explicitly directs FDA to prioritize psychedelic medicines for depression, PTSD, and suicidality and to award National Priority Vouchers to qualifying drugs—NRXP has already applied for this voucher. Congressional appropriations language reinforcing the use of RWE in approvals for suicidal depression and PTSD creates a bipartisan, structural shift in regulatory strategy that NRXP is uniquely positioned to exploit. With Fast Track designation already secured, the company is entitled to priority review, and the potential voucher could yield significant financial upside through resale or tax savings. The broader indication sought—depression in patients who may have suicidality, affecting over 10 million Americans—dwarfs the narrow suicidality-only label of SPRAVATO, which generates ~$2 billion annually despite lacking suicidality reduction in its labeling. NRXP’s data foundation, combining over 1,000 patients from clinical trials with 65,000+ real-world records, provides a robust, real-world-validated dataset that aligns with FDA’s evolving stance, potentially enabling faster approval and broader adoption than anticipated.
The MIND1 trial for NRX-101 represents a high-potential, non-dilutive catalyst that could transform the depression treatment landscape by combining D-cycloserine with robotic-assisted TMS via an accelerated ONE-D protocol. FDA clearance to proceed, anticipated federal funding from military treatment facilities, and collaboration with HOPE Therapeutics clinics and academic institutions create a uniquely supported trial design targeting 400 participants. Preclinical and early clinical data suggest that adding D-cycloserine to TMS doubles clinical response and increases remission eightfold for suicidality—effects that, if replicated, would position NRX-101 as a breakthrough adjunct therapy in a market exceeding $1 billion. The involvement of NRx Defense Systems, led by a former DARPA program manager, and the partnership with Zeta Surgical—whose AI-powered neuro navigation platform has FDA 510(k) clearance—adds technological differentiation and credibility. Crucially, the trial’s focus on frontline troops and first responders addresses a critical unmet need: depression and PTSD carry a fivefold increased risk in these populations, and standard antidepressants often disqualify them from deployment, making a rapid, effective non-pharmacological alternative both a healthcare imperative and a force readiness priority. If positive, the MIND1 trial could support approval based on a single study due to the heightened regulatory priority around suicidality, reducing future development costs and accelerating time-to-market. This pipeline asset remains under-discussed in investor conversations focused on KETAFREE and NRX-100, yet it offers a distinct, high-impact pathway to long-term value creation.

▼ Bear case

Despite optimistic messaging, NRXP’s KETAFREE launch faces significant commercialization risks that management underemphasized, particularly regarding market adoption and competitive dynamics. While the company highlights the ASHP-listed shortage of ketamine, it did not address whether hospital formularies—dominated by group purchasing organizations (GPOs) and entrenched supplier contracts—will readily switch to a new entrant, even with preservative-free and U.S.-made advantages. The reliance on Glenn Tyson’s Indivior experience may not translate directly, as SUBLOCADE benefited from a unique reimbursement pathway and limited competition, whereas ketamine faces generic competition from multiple established suppliers once the shortage eases. Management avoided discussing pricing strategy, leaving unaddressed how NRXP will compete on cost against lower-priced generic ketamine, especially if hospital procurement prioritizes price over preservative-free status. Furthermore, the claim that clinics cannot obtain ketamine from wholesalers was not substantiated with data on wholesaler policies or contractual barriers, and the assumption that clinics will readily adopt a new FDA-approved product ignores potential inertia in clinical workflows, reimbursement hesitancy, and the entrenched use of compounding pharmacies for customized dosing. The blow-fill seal manufacturing advantage, while real, does not guarantee market acceptance if clinicians perceive no meaningful clinical difference from existing ketamine, particularly given that the preservative benzethonium chloride has been used for decades without widespread safety alerts in clinical ketamine use.
The regulatory path for NRX-100, while buoyed by executive support and real-world evidence, remains uncertain and potentially overstated in its likelihood of success. Management emphasized the FDA’s openness to RWE but did not disclose critical details about the statistical analysis plan still under review, leaving open the risk that the FDA may demand additional stratification, confounders adjustment, or subgroup analyses that could delay or complicate the submission. The reliance on Osmind’s data introduces validation risk: while the company cites strong concordance with MADRS and PHQ-9, it did not address potential biases in real-world data collection, such as missing data, non-standardized dosing, or lack of placebo control, which regulators often scrutinize closely in psychiatric indications. Furthermore, the executive order and Congressional language, while supportive, are not binding on FDA and do not guarantee approval, priority review, or voucher award—NRXP’s application for the National Priority Voucher remains pending, and the agency has broad discretion in granting such incentives. The company avoided discussing the possibility that FDA may still require a confirmatory trial despite the Fast Track designation, particularly given the history of mixed results in psychedelic-like therapeutics. With SPRAVATO’s approval pathway requiring a REMS program and limited abuse potential data, NRX-100 may face similar or heightened scrutiny, especially given ketamine’s known dissociative effects and abuse potential, which management did not adequately address in context of risk evaluation and mitigation strategies.
The MIND1 trial for NRX-101, while scientifically intriguing, carries substantial execution and regulatory risks that were downplayed during the call. The trial’s dependence on nondilutive federal funding from military sites introduces uncertainty—management anticipating support did not confirm committed contracts or funding timelines, leaving the trial vulnerable to delays if federal approvals or budget allocations stall. The collaboration with Zeta Surgical, while technologically advanced, adds complexity: the AI-powered neuro navigation platform’s integration with robotic-assisted TMS and NRX-101 dosing has not been validated in large-scale trials, and any technical failure or usability issue could compromise data integrity. Furthermore, the claim that D-cycloserine increases remission eightfold when added to TMS is based on preliminary data that management did not contextualize—no details were given on effect size durability, long-term follow-up, or comparative effectiveness against established treatments like esketamine or SSRIs. The trial’s focus on frontline responders, while addressing a meaningful need, may limit generalizability and complicate labeling expansion if efficacy is perceived as population-specific. Most critically, management did not discuss the potential for NRX-101 to require a new NDA or significant additional data if used as an adjunct, nor did they address whether the combination product would face heightened scrutiny due to the novelty of pairing a repurposed antibiotic (D-cycloserine) with neuromodulation. Without clear delineation of regulatory pathway or de-risking milestones, the MIND1 trial remains a speculative catalyst with significant binary risk.

Despite optimistic messaging, NRXP’s KETAFREE launch faces significant commercialization risks that management underemphasized, particularly regarding market adoption and competitive dynamics. While the company highlights the ASHP-listed shortage of ketamine, it did not address whether hospital formularies—dominated by group purchasing organizations (GPOs) and entrenched supplier contracts—will readily switch to a new entrant, even with preservative-free and U.S.-made advantages. The reliance on Glenn Tyson’s Indivior experience may not translate directly, as SUBLOCADE benefited from a unique reimbursement pathway and limited competition, whereas ketamine faces generic competition from multiple established suppliers once the shortage eases. Management avoided discussing pricing strategy, leaving unaddressed how NRXP will compete on cost against lower-priced generic ketamine, especially if hospital procurement prioritizes price over preservative-free status. Furthermore, the claim that clinics cannot obtain ketamine from wholesalers was not substantiated with data on wholesaler policies or contractual barriers, and the assumption that clinics will readily adopt a new FDA-approved product ignores potential inertia in clinical workflows, reimbursement hesitancy, and the entrenched use of compounding pharmacies for customized dosing. The blow-fill seal manufacturing advantage, while real, does not guarantee market acceptance if clinicians perceive no meaningful clinical difference from existing ketamine, particularly given that the preservative benzethonium chloride has been used for decades without widespread safety alerts in clinical ketamine use.
The regulatory path for NRX-100, while buoyed by executive support and real-world evidence, remains uncertain and potentially overstated in its likelihood of success. Management emphasized the FDA’s openness to RWE but did not disclose critical details about the statistical analysis plan still under review, leaving open the risk that the FDA may demand additional stratification, confounders adjustment, or subgroup analyses that could delay or complicate the submission. The reliance on Osmind’s data introduces validation risk: while the company cites strong concordance with MADRS and PHQ-9, it did not address potential biases in real-world data collection, such as missing data, non-standardized dosing, or lack of placebo control, which regulators often scrutinize closely in psychiatric indications. Furthermore, the executive order and Congressional language, while supportive, are not binding on FDA and do not guarantee approval, priority review, or voucher award—NRXP’s application for the National Priority Voucher remains pending, and the agency has broad discretion in granting such incentives. The company avoided discussing the possibility that FDA may still require a confirmatory trial despite the Fast Track designation, particularly given the history of mixed results in psychedelic-like therapeutics. With SPRAVATO’s approval pathway requiring a REMS program and limited abuse potential data, NRX-100 may face similar or heightened scrutiny, especially given ketamine’s known dissociative effects and abuse potential, which management did not adequately address in context of risk evaluation and mitigation strategies.
The MIND1 trial for NRX-101, while scientifically intriguing, carries substantial execution and regulatory risks that were downplayed during the call. The trial’s dependence on nondilutive federal funding from military sites introduces uncertainty—management anticipating support did not confirm committed contracts or funding timelines, leaving the trial vulnerable to delays if federal approvals or budget allocations stall. The collaboration with Zeta Surgical, while technologically advanced, adds complexity: the AI-powered neuro navigation platform’s integration with robotic-assisted TMS and NRX-101 dosing has not been validated in large-scale trials, and any technical failure or usability issue could compromise data integrity. Furthermore, the claim that D-cycloserine increases remission eightfold when added to TMS is based on preliminary data that management did not contextualize—no details were given on effect size durability, long-term follow-up, or comparative effectiveness against established treatments like esketamine or SSRIs. The trial’s focus on frontline responders, while addressing a meaningful need, may limit generalizability and complicate labeling expansion if efficacy is perceived as population-specific. Most critically, management did not discuss the potential for NRX-101 to require a new NDA or significant additional data if used as an adjunct, nor did they address whether the combination product would face heightened scrutiny due to the novelty of pairing a repurposed antibiotic (D-cycloserine) with neuromodulation. Without clear delineation of regulatory pathway or de-risking milestones, the MIND1 trial remains a speculative catalyst with significant binary risk.

Health Care Organization, Revenue Sources Breakdown of Revenue (2025)

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	OCS	Oculis Holding AG	68,785.72 Bn	-32.10 Bn	-	-
2	NBTX	Nanobiotix S.A.	1,895.57 Bn	0.00 Bn	56,599.40	0.11 Bn
3	ONC	BeOne Medicines Ltd.	471.35 Bn	0.00 Bn	82.13	0.96 Bn
4	NCNA	NuCana plc	279.75 Bn	0.00 Bn	-	-
5	VRTX	Vertex Pharmaceuticals Inc / Ma	120.24 Bn	0.00 Bn	9.84	-
6	REGN	Regeneron Pharmaceuticals, Inc.	67.80 Bn	0.00 Bn	4.54	1.99 Bn
7	BLTE	Belite Bio, Inc	62.51 Bn	367.72 Bn	-	-
8	ARGX	Argenx Se	57.38 Bn	0.00 Bn	12.31	-

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Health Care Organization, Revenue Sources Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Health Care Organization, Revenue Sources Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password